<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139667</url>
  </required_header>
  <id_info>
    <org_study_id>FDASU-RECD123</org_study_id>
    <nct_id>NCT05139667</nct_id>
  </id_info>
  <brief_title>Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus</brief_title>
  <official_title>Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus ( A Randomized Controlled Clinical Trial With Immunohistochemical Analysis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      tacrolimus has been widely used as an immunosuppressant. the objective of this study was to&#xD;
      evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to&#xD;
      tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to&#xD;
      investigate the effect of topical tacrolimus or corticosteroids on the expression of&#xD;
      caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically&#xD;
      analysis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      thirty patients with erosive or atrophic OLP were randomly assigned into three equal groups&#xD;
      to receive topical steroid ( triamcinolone acetonide 0.1%), four times per day ( Group 1),&#xD;
      tacrolimus paste 0.1% four times per day ( Group 2) , and tacrolimus patch 2 times per day (&#xD;
      Group 3). all groups are given treatment for 8 weeks and 4 weeks follow up period without&#xD;
      treatment. Photographs of the most severe lesion were taken ( marker lesion ) in each patient&#xD;
      and analyzed for total ulcerative area (TUA), total atrophic area (TAA). patients were also&#xD;
      assessed using clinical scores (CS) and visual analogue scale (VAS). pre treatment and post&#xD;
      treatment specimens were immunohistochemically stained to detect expression of caspase-3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">October 20, 2021</completion_date>
  <primary_completion_date type="Actual">October 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>treatment of oral lichen planus</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>oral lichen planus</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>clinical score</measure>
    <time_frame>change from baseline at 12 weeks</time_frame>
    <description>&quot;0&quot; represnted no lesion/normal mucosa, &quot;1&quot; mild white stria / no erythematous area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>caspase-3</measure>
    <time_frame>change from base line at 8 weeks</time_frame>
    <description>caspase-3 cells count in immunostained section</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>tacrolimus/corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical corticosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical tacrolimus patch and tacrolimus paste</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid Topical</intervention_name>
    <description>topical tacrolimus and corticosteroids</description>
    <arm_group_label>corticosteroids</arm_group_label>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_label>tacrolimus/corticosteroid</arm_group_label>
    <other_name>tacrolimus paste and patch topical</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically and histologically proven painful bullous/erosive or atrophic forms of OLP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lichenoid lesions smoking systemic conditions pregnancy or breast feeding known&#xD;
             hypersnstivity or severe adverse effects to the treatment drugs or to any ingredient&#xD;
             of their preparation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Noha Dawoud</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Noha Dawoud</investigator_full_name>
    <investigator_title>assistant lecturer of oral medicine and diagnosis</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

